In conclusion, the results suggest that the expression patterns and clinical significance of ATP7A and ATP7B in glioma differ: high ATP7A expression is associated with poor prognosis, while ATP7B downregulation also predicts poor clinical outcomes. The gene discussed is ATP7A; the disease is central nervous system cancer.